Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6% of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11% of normal) were required to reduce urinary GAG excretion; and high levels (≥50% of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.
Get full access to this article
View all access options for this article.
References
1.
AbreuS., HaydenJ., BertholdP., ShapiroI.M., DeckerS., PattersonD., HaskinsM.1995. Growth plate pathology in feline mucopolysaccharidosis VI. Calcif. Tissue Int., 57:185–190.
2.
AroraR.S., MercerJ., ThornleyM., TyleeK., WraithJ.E.2007. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation. J. Inherit. Metab. Dis., 30:821.
3.
BergstromS.K., QuinnJ.J., GreensteinR., AscensaoJ.1994. Long-term follow-up of a patient transplanted for Hunter's disease type IIB: A case report and literature review. Bone Marrow Transplant., 14:653–658.
4.
BiffiA., NaldiniL.2005. Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum. Gene Ther., 16:1133–1142.
5.
BloomW., FawcettD.W.1994. A Textbook of Histology. W.B. Saunders: Philadelphia.
6.
BrooksD.A., KingB.M., CrawleyA.C., ByersS., HopwoodJ.J.1997. Enzyme replacement therapy in mucopolysaccharidosis VI: Evidence for immune responses and altered efficacy of treatment in animal models. Biochim. Biophys. Acta, 1361:203–216.
7.
BrooksD.A., HopwoodJ.J., KingB.M.1998. Immune response to enzyme replacement therapy: Clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. Biochim. Biophys. Acta, 1407:163–172.
8.
ChangP.L., RosaN.E., DavidsonR.G.1981. Differential assay of arylsulfatase A and B activities: A sensitive method for cultured human cells. Anal. Biochem., 117:382–389.
9.
CironC., DesmarisN., ColleM.A., RaoulS., JoussemetB., VerotL., AusseilJ., FroissartR., RouxF., CherelY., FerryN., LajatY., SchwartzB., VanierM.T., MaireI., TardieuM., MoullierP., HeardJ.M.2006. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol., 60:204–213.
10.
CrawleyA.C., BrooksD.A., MullerV.J., PetersenB.A., IsaacE.L., BielickiJ., KingB.M., BoulterC.D., MooreA.J., FazzalariN.L., AnsonD.S., ByersS., HopwoodJ.J.1996. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest., 97:1864–1873.
11.
DahmsN.M., LobelP., KornfeldS.1989. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem., 264:12115–12118.
12.
de JongJ.G., WeversR.A., LaarakkersC., PoorthuisB.J.1989. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: A rapid screening procedure for mucopolysaccharidoses. Clin. Chem., 35:1472–1477.
13.
DesnickR.J., SchuchmanE.H.2002. Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders. Nat. Rev. Genet., 3:954–966.
14.
DicksonP., PeinovichM., McEnteeM., LesterT., LeS., KriegerA., ManuelH., JabagatC., PassageM., KakkisE.D.2008. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J. Clin. Invest., 118:2868–2876.
15.
EversM., SaftigP., SchmidtP., HafnerA., McLoghlinD.B., SchmahlW., HessB., Von FiguraK., PetersC.1996. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc. Natl. Acad. Sci. U.S.A., 93:8214–8219.
16.
FazeliM., Zarkesh-EsfahaniH., WuZ., MaamraM., BidlingmaierM., PockleyA.G., WatsonP., MatareseG., StrasburgerC.J., RossR.J.2006. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J. Immunol. Methods, 312:190–200.
17.
FieldR.E., BuchananJ.A., CopplemansM.G., AichrothP.M.1994. Bone-marrow transplantation in Hurler's syndrome: Effect on skeletal development. J. Bone Joint Surg. Br., 76:975–981.
18.
FieldsP.A., ArrudaV.R., ArmstrongE., ChuK., MingozziF., HagstromJ.N., HerzogR.W., HighK.A.2001. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol. Ther., 4:201–210.
19.
FrancoL.M., SunB., YangX., BirdA., ZhangH., SchneiderA., BrownT., YoungS.P., ClayT.M., AmalfitanoA., ChenY.T., KoeberlD.D.2005. Evasion of immune responses to introduced human acid α-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther., 12:876–884.
20.
GaoG., QuG., BurnhamM.S., HuangJ., ChirmuleN., JoshiB., YuQ.C., MarshJ.A., ConceicaoC.M., WilsonJ.M.2000. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther., 11:2079–2091.
21.
Garcia-RiveraM.F., Colvin-WanshuraL.E., NelsonM.S., NanZ., KhanS.A., RogersT.B., MaitraI., LowW.C., GuptaP.2007. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res. Bull., 74:429–438.
22.
GheeJ.Y., HanD.H., SongH.K., KimW.Y., KimS.H., YoonH.E., ChoiB.S., KimY.S., KimJ., YangC.W.2008. The role of macrophage in the pathogenesis of chronic cyclosporine-induced nephropathy. Nephrol. Dial. Transplant., 23:4061–4069.
23.
GracaL.2008. CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade. Acta Reumatol. Port., 33:267–276.
24.
GullingsrudE.O., KrivitW., SummersC.G.1998. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation: Longer follow-up. Ophthalmology, 105:1099–1105.
25.
HarmatzP., KramerW.G., HopwoodJ.J., SimonJ., ButenskyE., SwiedlerS.J.2005. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): A phase I/II study. Acta Paediatr. Suppl., 94:61–68discussion 57.
26.
HeldermonC.D., HennigA.K., OhlemillerK.K., OgilvieJ.M., HerzogE.D., BreidenbachA., VoglerC., WozniakD.F., SandsM.S.2007. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS ONE, 2:e772.
27.
HerskhovitzE., YoungE., RainerJ., HallC.M., LidchiV., ChongK., VellodiA.1999. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): Long-term follow-up. J. Inherit. Metab. Dis., 22:50–62.
28.
HerzogR.W., MountJ.D., ArrudaV.R., HighK.A., LothropC.D.Jr.2001. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther., 4:192–200.
29.
HoogerbruggeP.M., BrouwerO.F., BordigoniP., RingdenO., KapaunP., OrtegaJ.J., O'MearaA., CornuG., SouilletG., FrappazD., BlancheS., FischerA., RingdenO.European Group for Bone Marrow Transplantation. 1995. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet, 345:1398–1402.
30.
HopwoodJ.J., MorrisC.P.1990. The mucopolysaccharidoses: Diagnosis, molecular genetics and treatment. Mol. Biol. Med., 7:381–404.
31.
HopwoodJ.J., VellodiA., ScottH.S., MorrisC.P., LitjensT., ClementsP.R., BrooksD.A., CooperA., WraithJ.E.1993. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J. Inherit. Metab. Dis., 16:1024–1033.
32.
HsuW.K., FeeleyB.T., KrenekL., StoutD.B., ChatziioannouA.F., LiebermanJ.R.2007. The use of 18F-fluoride and 18F-FDG PET scans to assess fracture healing in a rat femur model. Eur. J. Nucl. Med. Mol. Imaging, 34:1291–1301.
33.
JacobsonP., NgJ., RatanatharathornV., UbertiJ., BrundageR.C.2001. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant., 28:753–758.
34.
JohnsonP.W., OrchardK.2002. Bone marrow transplants. BMJ, 325:348–349.
35.
JonesM.Z., BrumfieldL.K., KingB.M., HopwoodJ.J., ByersS.1998. Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: Plasma clearance, tissue distribution, and cellular uptake in the rat. J. Mol. Neurosci., 11:223–232.
36.
KanekoM., TomitaT., NakaseT., OhsawaY., SekiH., TakeuchiE., TakanoH., ShiK., TakahiK., KominamiE., UchiyamaY., YoshikawaH., OchiT.2001. Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology, 40:247–255.
37.
KoseogluS.T., HarmatzP., TurbevilleS., NicelyH.2008. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy. Int. Ophthalmol., 29:267–269.
38.
KuniedaT., SimonaroC.M., YoshidaM., IkadaiH., LevanG., DesnickR.J., SchuchmanE.H.1995. Mucopolysaccharidosis type VI in rats: Isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics, 29:582–587.
39.
KuypersD.R.2005. Immunosuppressive drug monitoring: What to use in clinical practice today to improve renal graft outcome. Transpl. Int., 18:140–150.
40.
LiP., ThompsonJ.N., HugG., HuffmanP., ChuckG.1996. Biochemical and molecular analysis in a patient with the severe form of Hunter syndrome after bone marrow transplantation. Am. J. Med. Genet., 64:531–535.
LorinczA.E.1978. The mucopolysaccharidoses: Advances in understanding and treatment. Pediatr. Ann., 7:104–122.
43.
MaX., LiuY., TittigerM., HennigA., KovacsA., PopelkaS., WangB., HeratiR., BiggM., PonderK.P.2007. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol. Ther., 15:889–902.
44.
MalatackJ.J., ConsoliniD.M., BayeverE.2003. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr. Neurol., 29:391–403.
45.
MauryS., LitvinovaE., BoyerO., BenardL., BruelS., KlatzmannD., CohenJ.L.2002. Effect of combined cytostatic cyclosporin A and cytolytic suicide gene therapy on the prevention of experimental graft-versus-host disease. Gene Ther., 9:201–207.
46.
MiaoC.H., YeP., ThompsonA.R., RawlingsD.J., OchsH.D.2006. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood, 108:19–27.
47.
MingozziF., HighK.A.2007. Immune responses to AAV in clinical trials. Curr. Gene Ther., 7:316–324.
48.
MingozziF., LiuY.L., DobrzynskiE., KaufholdA., LiuJ.H., WangY., ArrudaV.R., HighK.A., HerzogR.W.2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest., 111:1347–1356.
49.
MonvilleC., TorresE.M., DunnettS.B.2006. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J. Neurosci. Methods, 158:219–223.
50.
NapoliK.L., WangM.E., StepkowskiS.M., KahanB.D.1997. Distribution of sirolimus in rat tissue. Clin. Biochem., 30:135–142.
51.
NassarP.O., NassarC.A., GuimaraesM.R., AquinoS.G., AndiaD.C., MuscaraM.N., SpolidorioD.M., RossaC.Jr., SpolidorioL.C.2008. Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats. J. Periodontal Res., 44:479–488.
52.
NeufeldE., MuenzerJ.2001. The mucopolysaccharidoses. ScriverR., BeaudetA.L., SlyW.S., ValleD.The Metabolic and Molecular Bases of Inherited Disease, 8th3. McGraw-Hill: New York, 3421–3452.
53.
NuttallJ.D., BrumfieldL.K., FazzalariN.L., HopwoodJ.J., ByersS.1999. Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif. Tissue Int., 65:47–52.
54.
PassiniM.A., BuJ., FidlerJ.A., ZieglerR.J., FoleyJ.W., DodgeJ.C., YangW.W., ClarkeJ., TaksirT.V., GriffithsD.A., ZhaoM.A., O'RiordanC.R., SchuchmanE.H., ShihabuddinL.S., ChengS.H.2007. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl. Acad. Sci. U.S.A., 104:9505–9510.
55.
PernuH.E., KnuuttilaM.L.2001. Macrophages and lymphocyte subpopulations in nifedipine- and cyclosporin A-associated human gingival overgrowth. J. Periodontol., 72:160–166.
56.
PitzS., OgunO., ArashL., MiebachE., BeckM.2009. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?Graefes Arch. Clin. Exp. Ophthalmol., 247:975–980.
57.
PodderH., StepkowskiS.M., NapoliK.L., ClarkJ., VeraniR.R., ChouT.C., KahanB.D.2001. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J. Am. Soc. Nephrol., 12:1059–1071.
58.
PonderK.P., WangB., WangP., MaX., HeratiR., WangB., CullenK., O'DonnellP., EllinwoodN.M., TraasA., PrimeauT.M., HaskinsM.E.2006. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol. Ther., 14:5–13.
59.
RohrbachM., ClarkeJ.T.2007. Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy. Drugs, 67:2697–2716.
60.
SacksM.S., David MerrymanW., SchmidtD.E.2009. On the biomechanics of heart valve function. J. Biomech., 42:1804–1824.
61.
SakaiM., HobaraN., HokamaN., KameyaH., OhshiroS., SakanashiM., SaitohH.2004. Increased bioavailability of tacrolimus after rectal administration in rats. Biol. Pharm. Bull., 27:1480–1482.
62.
ShapiroE.G., LockmanL.A., BalthazorM., KrivitW.1995. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis., 18:413–429.
63.
ShullR.M., KakkisE.D., McEnteeM.F., KaniaS.A., JonasA.J., NeufeldE.F.1994. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. U.S.A., 91:12937–12941.
64.
SimonaroC.M., D'AngeloM., HaskinsM.E., SchuchmanE.H.2005. Joint and bone disease in mucopolysaccharidoses VI and VII: Identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res., 57:701–707.
65.
SpolidorioL.C., MarcantonioE.Jr., SpolidorioD.M., NassarC.A., NassarP.O., MarcantonioR.A., RossaC.Jr.2007. Alendronate therapy in cyclosporine-induced alveolar bone loss in rats. J. Periodontal Res., 42:466–473.
66.
TessitoreA., FaellaA., O'MalleyT., CotugnoG., DoriaM., KuniedaT., MatareseG., HaskinsM., AuricchioA.2008. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol. Ther., 16:30–37.
67.
TomatsuS., MontanoA.M., OhashiA., GutierrezM.A., OikawaH., OgumaT., DungV.C., NishiokaT., OriiT., SlyW.S.2008. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum. Mol. Genet., 17:815–824.
68.
VellodiA., YoungE., CooperA., LidchiV., WinchesterB., WraithJ.E.1999. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis., 22:638–648.
69.
WangC.C., HwuW.L., LinK.H.2008. Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation. World J. Pediatr., 4:152–154.
70.
XiaoW., ChirmuleN., BertaS.C., McCulloughB., GaoG., WilsonJ.M.1999. Gene therapy vectors based on adeno-associated virus type 1. J. Virol., 73:3994–4003.
71.
XuL., MangoR.L., SandsM.S., HaskinsM.E., EllinwoodN.M., PonderK.P.2002. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol. Ther., 6:745–758.
72.
YanoS., MoseleyK., PavlovaZ.2009. Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy. J. Inherit. Metab. Dis.(in press).
73.
YoshidaM., IkadaiH., MaekawaA., TakahashiM., NagaseS.1993. Pathological characteristics of mucopolysaccharidosis VI in the rat. J. Comp. Pathol., 109:141–153.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
